A New Tone at the FDA on Compounded Hormones—But We Can’t Let Up
The FDA’s new, more open tone on compounded bioidentical hormones is a promising shift—but without sustained public pressure, meaningful change is far from guaranteed. Action Alert! THE TOPLINE In a surprising turn, FDA Commissioner Marty Makary made a comment recently that may signal a long-overdue shift in the agency’s position on compounded bioidentical hormone therapy […]

